Your browser is no longer supported. Please, upgrade your browser.
ADVM Adverum Biotechnologies, Inc. daily Stock Chart
ADVM [NASD]
Adverum Biotechnologies, Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own11.22% Shs Outstand64.28M Perf Week-7.79%
Market Cap677.51M Forward P/E- EPS next Y-1.14 Insider Trans0.00% Shs Float58.29M Perf Month16.85%
Income-61.20M PEG- EPS next Q-0.30 Inst Own87.40% Short Float15.99% Perf Quarter67.57%
Sales0.30M P/S2258.37 EPS this Y-12.40% Inst Trans5.02% Short Ratio5.89 Perf Half Y-8.43%
Book/sh2.55 P/B4.13 EPS next Y-12.90% ROA-28.80% Target Price10.40 Perf Year187.98%
Cash/sh2.52 P/C4.18 EPS next 5Y- ROE-33.50% 52W Range2.81 - 16.38 Perf YTD234.60%
Dividend- P/FCF- EPS past 5Y-36.80% ROI-38.20% 52W High-35.67% Beta2.76
Dividend %- Quick Ratio9.40 Sales past 5Y27.40% Gross Margin- 52W Low275.09% ATR0.67
Employees96 Current Ratio9.40 Sales Q/Q-62.50% Oper. Margin- RSI (14)56.26 Volatility6.54% 6.19%
OptionableYes Debt/Eq0.00 EPS Q/Q25.50% Profit Margin- Rel Volume0.38 Prev Close10.49
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume1.58M Price10.54
Recom2.60 SMA201.29% SMA5025.82% SMA20018.41% Volume605,505 Change0.48%
Oct-15-19Reiterated Chardan Capital Markets Neutral $6 → $10
Sep-13-19Reiterated Chardan Capital Markets Neutral $10 → $6
Jun-14-19Resumed Raymond James Mkt Perform
Nov-02-18Downgrade SunTrust Buy → Hold
Nov-02-18Downgrade Raymond James Outperform → Mkt Perform
Sep-21-18Initiated Cantor Fitzgerald Overweight
Aug-30-18Initiated SunTrust Buy $11
Feb-15-18Resumed Piper Jaffray Overweight $12
Oct-12-17Initiated Raymond James Outperform $6
Dec-14-19 08:41PM  Hedge Funds Dropped The Ball On Adverum Biotechnologies, Inc. (ADVM) Insider Monkey
Dec-02-19 10:53AM  Shareholder Alert - Adverum Biotechnologies - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire
07:28AM  Announcing: Adverum Biotechnologies (NASDAQ:ADVM) Stock Increased An Energizing 264% In The Last Three Years Simply Wall St.
Nov-25-19 08:56AM  Timing the Market, Is it Possible? - November 25, 2019 Zacks +5.68%
Nov-20-19 04:01PM  Adverum Biotechnologies to Participate in Piper Jaffrays 31st Annual Healthcare Conference GlobeNewswire
Nov-11-19 10:50AM  Adverum Biotechnologies Shareholder Alert Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire
Nov-08-19 05:07PM  Edited Transcript of ADVM earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents +7.06%
Nov-07-19 07:15PM  Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM  Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results GlobeNewswire
Nov-04-19 08:44AM  When Does Market Timing Actually Work? - November 04, 2019 Zacks
Oct-31-19 04:01PM  Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates GlobeNewswire +5.67%
Oct-30-19 04:01PM  Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer GlobeNewswire
Oct-29-19 12:37PM  Adverum Biotechnologies, Inc. (ADVM): Hedge Funds Getting Back In? Insider Monkey
Oct-24-19 08:00AM  Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD GlobeNewswire
Oct-23-19 08:00AM  Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress GlobeNewswire
Oct-14-19 08:36AM  The Market Timing Secrets No One Talks About - October 14, 2019 Zacks +15.12%
Oct-11-19 07:26PM  Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting GlobeNewswire
08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Sep-30-19 09:04AM  Adverum Biotechnologies Enters Oversold Territory Zacks
Sep-26-19 05:25PM  Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting GlobeNewswire
Sep-25-19 09:00AM  Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why Zacks
Sep-24-19 09:04AM  The Keys to Successfully Timing the Markets - September 24, 2019 Zacks
Sep-19-19 06:34AM  Should You Take Comfort From Insider Transactions At Adverum Biotechnologies, Inc. (NASDAQ:ADVM)? Simply Wall St.
Sep-13-19 12:29PM  A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019 Benzinga
10:06AM  Adverum Reports Data From Phase I Wet AMD Study, Stock Down Zacks
Sep-12-19 11:30AM  Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial Benzinga -50.33%
07:38AM  The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study Benzinga
02:41AM  Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD GlobeNewswire
Sep-04-19 04:01PM  Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting GlobeNewswire +9.24%
08:58AM  The Keys to Successfully Timing the Markets - September 04, 2019 Zacks
Aug-28-19 04:01PM  Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October GlobeNewswire
Aug-27-19 11:36AM  Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock? Zacks
Aug-16-19 11:23AM  What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? Zacks +7.46%
Aug-15-19 08:45PM  Edited Transcript of ADVM earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
09:57AM  The Keys to Successful Timing the Markets - August 15, 2019 Zacks
Aug-09-19 08:49PM  Adverum Biotechnologies, Inc. (ADVM) Q2 2019 Earnings Call Transcript Motley Fool -6.17%
Aug-08-19 05:15PM  Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates Zacks +5.21%
04:00PM  Adverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-06-19 09:54AM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks +6.86%
Aug-02-19 11:25AM  Tenet Healthcare (THC) Q2 Earnings: What's in the Cards? Zacks -12.61%
Aug-01-19 04:00PM  Adverum Biotechnologies Announces Board and Senior Management Changes GlobeNewswire
10:33AM  Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-31-19 09:12AM  2 Top Stocks to Buy in August Motley Fool
Jul-26-19 08:44AM  Is the Options Market Predicting a Spike in Adverum (ADVM) Stock? Zacks
Jul-25-19 04:00PM  Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates GlobeNewswire -7.87%
Jul-16-19 09:00AM  What Makes Adverum Biotechnologies (ADVM) a New Strong Buy Stock Zacks
Jul-15-19 04:00PM  Adverum Biotechnologies Appoints Senior Leaders GlobeNewswire
Jul-13-19 08:00AM  3 Top Growth Stocks to Buy Right Now Motley Fool
Jul-12-19 07:15AM  5 Best Biotech Stocks of 2019 So Far Motley Fool
Jul-11-19 08:58AM  Adverum (ADVM) Jumps: Stock Rises 5.1% Zacks
Jul-08-19 07:58AM  Adverum Biotechnologies to Present Data at Upcoming Conferences GlobeNewswire +22.53%
Jul-02-19 10:15AM  3 Biotechs That Have Doubled This Year (Acquisition Next?) Motley Fool
Jun-26-19 02:34PM  Did Hedge Funds Drop The Ball On Adverum Biotechnologies, Inc. (ADVM) ? Insider Monkey
Jun-23-19 09:28AM  The Adverum Biotechnologies (NASDAQ:ADVM) Share Price Has Gained 252%, So Why Not Pay It Some Attention? Simply Wall St.
Jun-10-19 09:00AM  Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD GlobeNewswire
May-24-19 09:44AM  Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue? Zacks
May-22-19 11:34AM  Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN Zacks
May-20-19 04:14PM  Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study Zacks
May-19-19 09:00AM  3 Biotech Stocks That Soared Last Week: Are They Buys? Motley Fool
May-17-19 08:00PM  Tallgrass Energy Barrons.com +11.32%
09:00AM  All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy Zacks
08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
May-16-19 09:00AM  Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD GlobeNewswire +26.05%
May-11-19 02:36AM  Tilray (TLRY) to Report Q1 Earnings: What's in the Cards? Zacks
May-10-19 03:45PM  Tilray (TLRY) to Report Q1 Earnings: What's in the Cards? Zacks
May-08-19 05:15PM  Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.45%
04:08PM  Adverum Biotechnologies: 1Q Earnings Snapshot Associated Press
04:00PM  Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
11:39AM  Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store? Zacks
May-02-19 04:30PM  Adverum Biotechnologies Announces Board Changes GlobeNewswire
06:00AM  Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting GlobeNewswire
May-01-19 10:33AM  Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-30-19 01:30PM  Adverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual Meeting GlobeNewswire
Apr-28-19 10:50PM  Is a Beat in the Offing for Humana's (HUM) Q1 Earnings? Zacks
Apr-25-19 07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
Apr-24-19 04:00PM  Adverum Biotechnologies Appoints Thomas Leung as Chief Financial Officer GlobeNewswire
Apr-17-19 07:48AM  The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO Benzinga
Apr-16-19 04:00PM  Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO GlobeNewswire
Apr-15-19 09:00AM  Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD GlobeNewswire +11.57%
Apr-05-19 12:25PM  What Kind Of Shareholders Own Adverum Biotechnologies, Inc. (NASDAQ:ADVM)? Simply Wall St.
Apr-01-19 04:01PM  Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer GlobeNewswire
Mar-18-19 09:00AM  Adverum Biotechnologies to Participate in Upcoming Conferences GlobeNewswire +5.02%
Mar-12-19 10:50AM  Adverum Biotechnologies (ADVM) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Mar-06-19 04:10PM  Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-28-19 04:10PM  Adverum to Present at the Cowen 39th Annual Health Care Conference GlobeNewswire -7.32%
Feb-13-19 04:10PM  Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-11-19 08:30AM  Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference GlobeNewswire +5.71%
Jan-30-19 07:30AM  Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-06-19 08:00PM  Adverum Biotechnologies Provides 2019 Outlook GlobeNewswire
Dec-20-18 08:30AM  Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -6.41%
Dec-12-18 04:32AM  What Bargains? Play 5 Stocks With Rising P/E Instead Zacks
01:09AM  Is Adverum Biotechnologies, Inc. (ADVM) A Good Stock To Buy? Insider Monkey
Dec-03-18 04:10PM  Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources GlobeNewswire
08:30AM  Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy GlobeNewswire
Nov-19-18 08:30AM  Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration GlobeNewswire
Nov-13-18 04:30PM  Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-08-18 08:30PM  Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:30PM  Adverum Biotechnologies: 3Q Earnings Snapshot Associated Press
04:10PM  Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
07:50AM  Investor Expectations to Drive Momentum within Consolidated Edison, MUELLER WATER PRODUCTS, Adverum Biotechnologies, Buckeye Partners, inTest, and Live Nation Entertainment Discovering Underlying Factors of Influence GlobeNewswire
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scopa James PaulDirectorMay 06Buy6.7120,000134,20020,000May 06 07:42 PM